The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus

Wenjuan Dong, a,b Heather Mead, c Lei Tian, a Jun-Gyu Park, d Juan I. Garcia, d Sierra Jaramillo, c Tasha Barr, a,b Daniel S. Kollath, c Vanessa K. Coyne, c Nathan E. Stone, c Ashley Jones, c Jianying Zhang, a Aimin Li, f Li-Shu Wang, g Martha Milanes-Yearsley, h Jordi B. Torrelles, d Luis Martinez-Sobrido, d Paul S. Keim, c Bridget Marie Barker, c Michael A. Caligiuri, i Jianhua Yu, a,b,i

a Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA
b Hematologic Malignancies Research Institute, City of Hope National Medical Center, Duarte, California, USA
c Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
d Disease Intervention and Prevention, and Population Health Programs, Texas Biomedical Research Institute, San Antonio, Texas, USA
e Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, California, USA
f Pathology Core, Shared Resources, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA
g Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
h Department of Pathology, The Ohio State University, Columbus, Ohio, USA

Wenjuan Dong and Heather Mead contributed equally to this work.

ABSTRACT A comprehensive analysis and characterization of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection model that mimics non-severe and severe coronavirus disease 2019 (COVID-19) in humans is warranted for understating the virus and developing preventive and therapeutic agents. Here, we characterized the K18-hACE2 mouse model expressing human (h)ACE2 in mice, controlled by the human keratin 18 (K18) promoter, in the epithelia, including airway epithelial cells where SARS-CoV-2 infections typically start. We found that intranasal inoculation with higher viral doses (2 × 10³ and 2 × 10⁴ PFU) of SARS-CoV-2 caused lethality of all mice and severe damage of various organs, including lung, liver, and kidney, while lower doses (2 × 10¹ and 2 × 10² PFU) led to less severe tissue damage and some mice recovered from the infection. In this hACE2 mouse model, SARS-CoV-2 infection damaged multiple tissues, with a dose-dependent effect in most tissues. Similar damage was observed in postmortem samples from COVID-19 patients. Finally, the mice that recovered from infection with a low dose of virus survived rechallenge with a high dose of virus. Compared to other existing models, the K18-hACE2 model seems to be the most sensitive COVID-19 model reported to date. Our work expands the information available about this model to include analysis of multiple infectious doses and various tissues with comparison to human postmortem samples from COVID-19 patients. In conclusion, the K18-hACE2 mouse model recapitulates both severe and non-severe COVID-19 in humans being dose-dependent and can provide insight into disease progression and the efficacy of therapeutics for preventing or treating COVID-19.

IMPORTANCE The pandemic of coronavirus disease 2019 (COVID-19) has reached nearly 240 million cases, caused nearly 5 million deaths worldwide as of October 2021, and has raised an urgent need for the development of novel drugs and therapeutics to prevent the spread and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To achieve this goal, an animal model that recapitulates the features of human COVID-19 disease progress and pathogenesis is greatly needed. In this study, we have comprehensively characterized a mouse model of SARS-CoV-2 infection using K18-hACE2 transgenic mice. We infected the mice with low and high doses of SARS-CoV-2 to study
the pathogenesis and survival in response to different infection patterns. Moreover, we compared the pathogenesis of the K18-hACE2 transgenic mice with that of the COVID-19 patients to show that this model could be a useful tool for the development of antiviral drugs and therapeutics.

**KEYWORDS** COVID-19, K18-hACE2, SARS-CoV-2, infectious disease, lung infection, mouse model

The global pandemic of coronavirus disease 2019 (COVID-19) caused by the extremely contagious RNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to nearly 240 million cases and nearly 5 million deaths worldwide as of October 2021 (https://www.worldometers.info/coronavirus/). The median time to development of symptoms is 5.1 days after exposure to SARS-CoV-2 (1). The median time from onset to clinical recovery for mild cases is approximately 2 weeks, with 3–6 weeks for patients with severe or advanced disease (2). The main symptoms, such as fever or chills, cough, shortness of breath, difficulty breathing, and sore throat normally ease after recovery; however, 3-17% of patients, especially the elderly and individuals with cancer and metabolic and immune disorders, develop rapid viral replication and severe lung damage, resulting in severe disease with greatly increased risk of death (3–6). Many groups are trying to understand this rapid disease progression, and studies suggest that it may involve an impaired immune response (7–9). A mouse model that appropriately mirrors the progression of the human disease should help the development of vaccines or therapeutics for COVID-19 and could be used as a conceptual basis for rapid response to future viral pandemics.

During infection with SARS-CoV-2, the coronavirus spike (S) glycoprotein promotes SARS-CoV-2 entry into host cells via the host receptor angiotensin converting enzyme 2 (ACE2) (10). K18-hACE2 transgenic mice, which were originally developed to study the infection of SARS-CoV, express human ACE2, the receptor used by SARS-CoV-2 to gain entry into cells (11). The human keratin 18 (K18) promoter is responsible for directing expression to airway epithelial cells, where respiratory infections usually begin. Recent research reported that this SARS-CoV-2 K18-hACE2 mouse infection model develops severe interstitial pneumonia with high viral copy numbers into the lungs and immune cell infiltration into the alveoli (12–16). A comprehensive analysis and characterization of this model will be useful for studying the mechanisms of pathogenesis by SARS-CoV-2 and developing preventive, therapeutic, and vaccinal agents.

In the current study, we evaluated K18-hACE2 transgenic mice in response to multiple infectious doses, using multiple tissues, to gain a better understanding of the response to SARS-CoV-2 infection. We also evaluated the response of K18-hACE2 mice to high-dose re-infection after recovery from a low-dose infection.

**RESULTS**

The K18-hACE2 model is a lethal infection model for SARS-CoV-2 infection. To understand the effects of SARS-CoV-2 viral dosage on pathogenesis and survival, we established an infection model using the K18-hACE2 transgenic mice, in which hACE2 expression is driven by the epithelial cell-specific promoter K18 in C57BL/6 mice (11). The mice were infected with SARS-CoV-2 WA-1/US (BEI Resources) at $2 \times 10^1$ PFU (lowest dose), $2 \times 10^2$ PFU (low dose), $2 \times 10^3$ PFU (high dose), $2 \times 10^4$ PFU (highest dose), or PBS vehicle control via intranasal inoculation. Mice were monitored for body weight change and survival or euthanized at various days postinfection (p.i.) to measure viral copy numbers and infectious viral loads as well as to determine pathology (Fig. 1A). We found that mouse body weight decreased in mice infected with $2 \times 10^3$ PFU and $2 \times 10^4$ PFU by day 4 p.i., whereas mice infected with $2 \times 10^1$ PFU and $2 \times 10^2$ PFU showed a less dramatic body weight decrease; a body weight decrease of 20% occurred at days 5–6 in the higher-dose groups, but took until day 10–11 for 80% of the mice in the low-dose groups (Fig. 1B). Up to 30% of the mice from the lower-dose groups started to gain weight by day 4 (for $2 \times 10^1$ PFU, lowest) and day 8 (for $2 \times 10^2$ PFU, low) (Fig. 1B),
indicating a recovery from the viral infection in low-dose groups. Consistent with body weight data, 90% of the mice infected with $2 \times 10^3$ PFU (high) or $2 \times 10^4$ PFU (highest) died approximately at day 7, whereas 50% of the mice infected with $2 \times 10^1$ PFU or $2 \times 10^2$ PFU died approximately at day 10 (Fig. 1C). One or two mice out of five infected with $2 \times 10^1$ PFU or $2 \times 10^2$ PFU, respectively, and none infected with $2 \times 10^3$ PFU or $2 \times 10^4$ PFU, recovered and survived until the end of follow-up on day 20 p.i. (Fig. 1C).

Expression distribution of viral genes in the tissues of K18-hACE2 mice infected with high or low doses of SARS-CoV-2. To further investigate the viral infection pattern, we used reverse transcriptase (RT)-PCR to measure viral spike protein RNA
levels in the brain, trachea, lung, liver, spleen, small intestine, stomach, large intestine, kidney, and testis. The mean viral copy numbers in tissues, where the dose-dependent effect is expected, were similar for the high and highest two doses in all tissues. Interestingly, mice infected with $2 \times 10^3$ PFU did not present virus in the spleen (Fig. 2A). We observed three types of dose-response relationships. In the stomach, there was a stepwise dose-response relationship. In the heart, liver, spleen, and small intestine, we observed a plateau, with the 3 higher dose groups having similar viral copy numbers. In the brain, large intestine, and testis, mice infected with $2 \times 10^3$ PFU and $2 \times 10^4$ PFU had similar viral copy numbers, and mice infected with $2 \times 10^5$ PFU and $2 \times 10^4$ PFU had similar viral copy numbers, but much higher than those of the two lower doses. This indicates that there are tissue-specific factors modulating the effect of dose on viral copy number. Viral RNA levels were high in the lungs of animals in all dose groups (Fig. 2A), consistent with the notion that the lung is an important site of infection, especially at lower viral doses. Viral RNA levels were also very high in the brain of mice infected with $2 \times 10^2$ PFU or $2 \times 10^3$ PFU. We used immunohistochemistry (IHC) to measure the expression of SARS-CoV-2 nucleocapsid protein (NP) in formalin-fixed, paraffin-embedded (FFPE) tissues, which confirmed the infection pattern in the lung and brain of the K18-hACE2 mice infected with a series of increasing viral doses, demonstrating that viral spread in tissues was also dose-dependent (Fig. 2B).

We also measured the infectious virus titer of the lung harvested from mice infected with the highest $2 \times 10^4$ PFU dose at different time points p.i., by a plaque assay on homogenized tissues. The infectious virus titer peaked at day 2 p.i. and then decreased in a time-dependent manner, reaching almost complete virus clearance at day 5 p.i. (Fig. 2C). Our data are consistent with a previous report using a higher dose (16).

To evaluate lung cell types that are susceptible to SARS-CoV-2 infection, we performed double IHC staining on samples from mice infected with different doses of SARS-CoV-2. We double stained lung sections for viral NP and CCL10, which is the marker of club (clara) cells, or surfactant protein C (SPC), the marker of alveolar epithelial type 2 cells, respectively. We found that some club cells and many alveolar type 2 cells co-localized with NP, suggesting they are susceptible to SARS-CoV-2 infection (Fig. 3A). Macrophages are a major immune cell population in the lung, where they act as a first-line defense against invading pathogens. We therefore used CD68 as a macrophage marker to examine if SARS-CoV-2 could infect tissue-resident macrophages in the lung. We noticed that that CD68 positive cells migrated dramatically to the lung in response to SARS-CoV-2 infection, although only a few macrophages stained positive for NP, suggesting that it could be possible for SARS-CoV-2 to suppress immune response via infection of lung macrophages (Fig. 3A). Consistent with the finding in the K18-hACE2 mouse model, in postmortem lung samples from COVID-19 patients, a few viral spike proteins (teal) were colocalized with alveolar epithelial type 2 cells (yellow) and CD68-positive cells (yellow) (Fig. 3B). These results are in line with another SARS-CoV-2 infection mouse model that uses CRISPR/Cas9 knock-in of hACE2 into Exon 2 of the mAce2 gene, as well as COVID-19 patient samples, which show SARS-CoV-2 in macrophages of pulmonary alveolus (14, 17). Given the high levels of SARS-CoV-2 in the brain, we examined whether neurons were infected with SARS-CoV-2. We found strong overlap between staining for the neuronal marker Neu and staining for NP (Fig. 3A).

Furthermore, human lung alveolar epithelial type II cells were injured significantly by SARS-CoV-2 virus infection (Fig. 3B). This was identified by the reduction of the number and stain intensity of SPC positive cells (yellow) in the infected lung of the postmortem samples compared to the non-infected lung (Fig. 3B). In COVID-19 lung sample #1, which has the highest virus amount (teal), the SPC positive cells are almost completely lost, whereas in the other lungs, SPC positive cells are low and have fallen off from the epithelium into the alveolar lumen (Fig. 3B). Our results indicated that the K18-hACE2 mice could be a suitable model for mimicking the infections of the COVID-19 patients.
FIG 2 Viral quantification in mice after SARS-CoV-2 infection. (A) Viral RNA levels are shown for the brain, trachea, lung, heart, liver, spleen, small intestine (SI), stomach, large intestine (LI), kidney, and testis. (B) Viral nucleocapsid protein (NP) was detected in the brain and lung of the mice infected with high and low doses of SARS-CoV-2 (scale bar, 40 μm). (C) Infectious virus loads in the lung at different time points. Mice were infected with 2 x 10^4 PFU at day 0. Lungs were collected and homogenized at indicated time points. The infectious virus loads were measured by a plaque assay. Data are presented as mean ± standard deviations. Statistical analyses were performed by one-way ANOVA with P values corrected for multiple comparisons by the Bonferroni test (n = 3 or 4 mice). *, P < 0.05; **, P < 0.01.
FIG 3  Viral distribution in mice after SARS-CoV-2 infection. (A) Representative images show double staining of NP (purple) with lung club (Clara) cells and alveolar type 2 cells using the markers CCL10 (yellow) and SPC (yellow), respectively, macrophages using the CD68 marker (yellow) (20× magnification for each), and neurons using the NeuN marker (yellow) in mice infected with high-dose SARS-CoV-2 (10× magnification, with 100× magnification for the boxed area in the 2 × 10^4 PFU group). Black arrows indicate double staining cells. (B) Representative images show double staining of the spike protein (teal) with alveolar type 2 cells using SPC (yellow) as a marker and macrophages using CD68 (yellow) as a marker in COVID-19 patient postmortem samples (20× magnification). Black arrows indicate double staining cells.

Dong et al. Journal of Virology

January Volume 96 Issue 1 e00964-21
Histopathology of tissues of K18-hACE2 mice infected with SARS-CoV-2. To assess disease severity, H&E staining was performed for histopathological evaluation in various organs from K18-hACE2 mice infected with a series of increasing doses of SARS-CoV-2. As expected, lung tissues showed the most severe damage. Mice in the low-dose groups showed an average of 30–60% more alveolar congestion and consolidation compared to uninfected mice (Fig. 4A). Some lung tissues showed alveolar hemorrhage as well as lymphocytic pneumonitis with alveolar thickening and peripheral parenchymal collapse. Lung damage in the high-dose groups was even more extensive, consisting of ~20% alveolar collapse with ruptured septa, as well as thickened alveolar and intra-alveolar septa. Parenchymal consolidation was evident in 50%
of the tissue, along with interstitial inflammation and pneumonitis (Fig. 4A). Similarly, trachea tissues showed mild epithelial damage in the lower-dose groups and more severe epithelial damage in the higher-dose groups. Consistent with the brain showing high viral gene expression for the higher-dose groups (Fig. 2A), brain tissues showed mild congestion in some mice from the low-dose groups, with more extensive congestion in the high-dose groups. In liver tissues, the low-dose groups showed several foci of spotty and patchy necrosis (focal perivenular), Kupffer cell hyperplasia, and focal portal inflammation; the high-dose groups also showed Kupffer cell hyperplasia along with congestion, reactive change, apoptotic hepatocytes, and focal lobular inflammation (Fig. 4A). In the spleen, the low-dose groups showed red pulp congestion while the high-dose groups also showed lymphoid hyperplasia and mild extramedullary hematopoiesis. The stomach and small and large intestines in the low-dose groups appeared normal but in the high-dose groups, the stomach showed reactive changes, diffuse epithelial sloughing, and chronic inflammation along the myenteric plexus, while the small and large intestine showed myenteric plexus inflammation. The testis in the low-dose groups also appeared normal but showed focal tubular damage and congestion in the high-dose groups. In the kidney, both the low-dose and high-dose groups showed cortical congestion, tubular damage, and focal tubular collapse. Meanwhile, both the low-dose and high-dose groups showed ischemic change and disarray in the heart (Fig. 4A). These findings indicate that SARS-CoV-2 infection damages multiple tissues, with a dose-dependent effect in most tissues.

To compare the pathological findings in the mouse model to COVID-19 patients, we also examined postmortem samples of COVID-19 patients. We identified congestion and inflammation in multiple organs, as well as epithelial damage and necrosis, which was consistent with our findings in the SARS-CoV-2-infected K18-hACE2 mouse model (Fig. 4B).

Expression of hACE2 in K18-hACE2 mice and human tissues. To better understand the infection pattern and virus distribution in this mouse model, we measured hACE2 RNA expression levels in various tissues of K18-hACE2 mice by RT-PCR. We found that, compared to the expression of hACE2 in the lung, there was also high expression in the brain, trachea, heart, stomach, small intestine, large intestine, kidney, and testis; whereas there was lower expression in the liver and spleen (Fig. 5A). We also confirmed the hACE2 expression in the brain, trachea, lung, and kidney of the k18-hACE2 mice at the protein level by IHC (Fig. 5B). The expression of hACE2 in the brain, trachea, and lung tissues in mice is consistent with the finding that they had the highest viral copy numbers (Fig. 5B vs. Fig. 2A), further confirming the K18-hACE2 mouse is a good model for studying in vivo SARS-CoV-2 infection. We also examined hACE2 expression in a human tissue array (Fig. 5C). We found that hACE2 is not only highly expressed in the lung but also in the stomach, small and large intestine, kidney, and testis. However, the expression of ACE2 in the human brain was not as high as in the brain of K18-hACE2 mice; this could be due to the insertion of the K18 promoter, which confers higher expression of hACE2 in the mouse model (Fig. 5C). This finding is consistent with another transgene driven by a human K18 regulatory element in mice (18).

Protective role of sera from previously infected mice and resistance of low-dose-infected surviving mice to high-dose rechallenge in the K18-hACE2 model. To evaluate if the sera from infected mice could protect the mice from viral infection, sera were collected from mice infected with $2 \times 10^4$ PFU SARS-CoV-2 at day 6 p.i. Collected sera were injected intravenously (i.v.) into virus-naïve mice. Two days later, mice receiving a prior dose of sera were intranasally infected with $2 \times 10^4$ PFU SARS-CoV-2, followed by an immediate i.v. injection of second dose of sera. Body weights of treated versus control mice were monitored daily. Mice treated with sera from infected mice showed a delayed and slower body weight drop compared to the untreated group (Fig. 6A), suggesting sera from infected mice had a protective effect on newly infected mice. Sera from infected mice did not significantly protect but show a trend against death after virus rechallenge, which might be due to the little amount of sera that we could collect to have a large enough sample size of transfused mice for the sera
protection experiments (Fig. 6B). Another reason for the moderate protective effect could be that the neutralizing antibody titer at day 6 may be low. To investigate this possibility, mice were infected with a lower dose, $1 \times 10^3$ PFU, so that some mice could survive long enough to collect sera. We collected sera at days 6 and 13 p.i. and measured relative anti-spike antibody levels by ELISA. Our data indeed showed that anti-spike antibody levels at day 6 p.i. were significantly lower than those at day 13 p.i. (Fig. 6C). These data indicate that the small amount of neutralizing antibody in sera collected at day 6 p.i. may not be enough for protecting mice receiving passive transfer of the sera.

In addition, we rechallenged the mice that survived $2 \times 10^4$ or $2 \times 10^5$ PFU infection with $2 \times 10^4$ PFU virus when they recovered to their initial body weight. We found that all mice survived the high-dose virus re-challenge without showing a substantial body weight drop, suggesting that recovery from low-dose infection conferred antiviral activity that protected against rechallenge with high dose virus (Fig. 6B). These results suggest that patients who survive from SARS-CoV-2 infection should be more resistant to the next infection with the same SARS-CoV-2 strain than people without prior infection.
DISCUSSION

The recent outbreak of SARS-CoV-2 that has claimed the lives of nearly 5 million people to date has led to an urgent need for a mouse infection model that accurately mirrors inoculation, development, and progression of the human disease termed COVID-19. The K18-hACE2 model was developed to study coronavirus infection (11). In the current study, we performed a comprehensive analysis of viral distribution and tissue pathology based on a range of inoculation doses and compared the results to observations in postmortem samples from COVID-19 patients. We found a dose-response relationship between infectious dose and loss of body weight, viral titer, tissue pathology, and mortality. Notably, there was not a uniform relationship between infectious dose and viral copy numbers, with some tissues accumulating virus at lower while others at higher copy number. We evaluated hACE2 levels in K18-hACE2 mice and found similarity to ACE2 levels in humans. We also showed that challenge with a low dose of SARS-CoV-2 protected against the lethality of rechallenge with a higher dose. Overall, our results indicate that low-dose infection in the K18-hACE2 model mimics non-severe COVID-19, while infection with higher doses mimics severe COVID-19.

FIG 6 Protective role of sera from previously infected mice and resistance of low dose-infected surviving mice to high-dose rechallenge in the K18-hACE2 model. Body weights (A) and survival (B) of mice treated with sera from previously infected mice and prior low dose-infected mice being challenged with a high dose of SARS-CoV-2. Mice with serum protection were infected with $2 \times 10^4$ PFU per mouse SASR-CoV-2 24 h after being infused with sera from mice infected with $2 \times 10^4$ PFU virus per mouse for 6 days. For the rechallenge, mice were infected with the low dose of $2 \times 10^3$ PFU or $2 \times 10^2$ PFU per mouse SASR-CoV-2 for 2 weeks and then were rechallenged with the high dose of $2 \times 10^4$ PFU per mouse SASR-CoV-2. Survival of mice was analyzed by the Kaplan–Meier method and the log-rank test. (C) Mice were infected with $1 \times 10^3$ PFU at day 0. Sera in the peripheral blood were collected via tail vein bleeding 6 days postinfection (dpi) or right before mice were sacrificed at 13 dpi. Relative anti-spike antibody levels were measured by ELISA. Data are presented as mean ± standard deviations. Statistical analyses were performed by one-way ANOVA with P values corrected for multiple comparisons by the Bonferroni test (n = 4 or 5 mice). **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Due to the unprecedented impact of the COVID-19 pandemic, many models of human COVID-19 are under investigation. In addition to the K18-hACE2 model, other mouse models have been described. Hassan et al. used replication-defective adenoviruses encoding human ACE2-tranduced mice to infect BALB/c mice, followed by SARS-CoV-2 infection, to model COVID-19 (15). Following infection by $10^5$ focus-forming units (FFU) of SARS-CoV-2, the body weight of mice was maintained but did not drop, therefore it seems that the model is not a lethal model. Using CRISPR/Cas9 technology to knock-in hACE2, Sun et al. established a model (14). In response to $4 \times 10^5$ PFU of SARS-CoV-2, the animals experienced robust viral replication in multiple tissues and interstitial pneumonia, but no obvious clinical symptoms or mortality; only 10% of aged mice lost their weight at day 3 p.i. and recovered. With the low incidence rate and very mild symptoms, this model is not ideal to recapitulate human COVID-19. This might be due to the nature of the knock-in with only one copy of hACE2 systemically existing in mice. Qin and colleagues developed a hACE2 transgenic mouse model with a mouse ACE2 promoter for SARS and used the model to study SARS-CoV-2 infection (13, 19). Infected by $1 \times 10^5$ TCID50 of SARS-CoV-2, the mouse body weights dropped at day 1 and continued until day 5, and then almost completely recovered on day 14 without lethality, suggesting that this model at least does not mimic severe COVID-19 patients. This might be due to lower promoter activity or gene expression of murine (m)ACE2 compared to the K18 promoter (19). Ostrowski et al. developed transgenic mice using the promoter of the human FOXJ1, a transcription factor required for differentiation of ciliated epithelial cells in the airway, to drive hACE2 expression (20). Jiang and colleagues used this model to study SARS-CoV-2 (12). Infected with $3 \times 10^4$ PFU SARS-CoV-2, among 10 mice, 2 had no infection, 4 had no drop in body weight, and 4 had body weight drops with 3 deaths and 1 recovery (12). In contrast, for the K18-hACE2 model that we characterized here, with the dose of $2 \times 10^3$ PFU, which is lower than the doses used in all above mouse models, all mice succumbed to infection with body weight drops and mortality of 100% by day 8. With lower dose infection such as $2 \times 10^3$ and $2 \times 10^2$ PFU, 30% of the mice recovered. Collectively, these suggest that the K18-hACE2 model is the most sensitive model for COVID-19, with ability to recapitulate aspects of human disease from both non-severe and severe COVID-19 patients.

Our results are supported by those from other groups (16, 21–24). This might be due to unique aspects of the K18-hACE2 model: 1) hACE2 is used, where in contrast other models including golden hamster, ferret, cat, Chinese tree shrew, and even mouse models with an endogenous ACE2 promoter recapitulate human expression levels (25); 2) multiple copies of hACE2 are placed in the murine genome (11), whereas one copy of hACE2 may not be ideal, evidenced by the knock-in study by Sun et al. (14); and 3) the human K18 promoter is likely stronger than the promoters in other models, such as the human FOXJ1 in the study by Jiang et al. (12). Apart from the animal models mentioned above, some mouse-adapted models of SARS-CoV-2 were also used for studying pathogenesis of SARS-CoV-2. In these models, recombinant mouse-adapted strains of SARS-CoV-2 bind the mouse ACE2 for viral entry; however, it is possible that accumulated mutations may not occur in humans (26–29).

The pathological damage in the lung and brain in the K18-hACE2 mouse infection model is similar to the clinical symptoms of COVID-19 patients, suggesting that this mouse model can recapitulate SARS-CoV-2 infection in humans. However, the K18-hACE2 mouse model was originally generated by inserting hACE2 in the mouse genome under the human K18 promoter, which may not result in the exact distribution of ACE2 expression as in humans. In fact, we observed high expression levels of hACE2 in mouse brains, correlating with a higher virus titer in the brain compared to most other organs or tissues; however, in the postmortem samples of humans, the hACE2 expression is very low. Nonetheless, brain infections with SARS-CoV-2 and deaths of patients from brain-specific COVID-19 have been frequently reported (30–32). Interestingly, our study showed that SARS-CoV-2 can infect neurons in an animal model, which is consistent with previous studies using human neuron organoids (33–35). It will be interesting to know whether this
neuronal infection causes taste and smell loss, commonly found in patients with COVID-19, as neuronal circuits respond to gustatory and olfactory cues (36).

In summary, we characterized the K18-hACE2 model for COVID-19 in comparison to human postmortem samples. The model shows dose-dependent sensitivity to SARS-CoV-2 infection. Infection with low doses recapitulates the disease observed in non-severe COVID-19 patients, while infection with higher doses recapitulates the disease observed in patients with severe COVID-19. The K18-hACE2 humanized COVID-19 mouse model is excellent to study COVID-19 and develop preventive and therapeutic drugs, as well as vaccines, for coronavirus diseases.

MATERIALS AND METHODS

Ethics statement. Mouse-model studies were performed in an animal biosafety level 3 (ABSL3) facility. The animal protocol of these studies was reviewed and approved by the institutional animal care and use committee (IACUC) of Northern Arizona University (protocol #20-005) and the committee of Texas Biomedical Research Institute (protocol #1718MU). Human postmortem COVID-19 patient samples were previously described (37) and were collected under the approval of the institutional review board.

Viruses, cells, and mice. The SARS-CoV-2 strain used in the mouse model was SARS-CoV-2/human/USA/WA-CDC-WA1/2020, which was obtained from the Biodefense and Emerging Infections Research Resources (BER Resources). The viruses were amplified using Vero-E6 cells (ATCC). Vero-E6 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) plus 10% fetal bovine serum (FBS) at 37°C and 5% CO₂. Cells were inoculated with virus at a multiplicity of infection (MOI) of 0.001 and cultured for 96 h. Then the supernatant was collected and titrated using a plaque assay.

The K18-hACE2 transgenic mice, in which the human keratin 18 (KRT18) promoter was used to direct human ACE2 expression, were purchased from The Jackson Laboratory.

Mouse infection. Female and male 6- to 8-week-old K18-hACE2 transgenic mice under the C57BL/6J background were anaesthetized and intranasally (i.n.) infected with SARS-CoV-2 virus at a dose of 2 × 10⁴, 2 × 10⁵, 2 × 10⁶, or 2 × 10⁷ PFU/mouse. The uninjected control mice were inoculated with phosphate-buffered saline (PBS). All the mice were observed and weighed daily. Peripheral blood was collected on day 6 from high dose groups and used for serum protection experiments. The mice were euthanized at day 6 postinfection, and the tissues were collected for further analysis.

Viral rechallenge model. The mice that survived i.n. infection with 2 × 10⁷ PFU and 2 × 10⁶ PFU of virus were rechallenged with 2 × 10⁵ PFU virus i.n. 2 weeks after the initial infection when they recovered to the initial body weight. The body weight was continuously monitored.

Serum protection model. Sera of the mice infected by 2 × 10⁷ PFU virus were collected at day 6 postinfection. Half of the sera were intraperitoneally injected into the non-infected mice 2 days before the mice were i.n. infected with 2 × 10⁵ PFU virus. The other half of the sera were intraperitoneally administered right before the infection.

Tissue preparation to detect viral copy number. Mouse tissues were collected, weighed, and immediately homogenized using an electric homogenizer (Thomas Scientific). After centrifugation at 1200 g for 10 min, the supernatant was isolated and used to detect viral RNA copy number by real-time PCR (see below).

Viral RNA copy number detection. Viral RNA was isolated from homogenized tissues using the PureLink RNA minikit (Invitrogen). A one-step RT-PCR kit (Bio-Rad) was used to detect the viral RNA using Applied Biosystems QuantStudio 12K Flex real-time PCR system with the following cycling protocol: reverse transcription at 50°C for 10 min; hot start at 95°C for 10 min; and 40 cycles of denaturation at 95°C for 10 s and annealing at 60°C for 30 s. The primer sequences were CoV2-S_19F (5'-GCTGAACATGTCAACAACTC-3') and CoV2-S_143R (5'-GCAATGATGGATTGACTAGC-3'), which were designed to target a 125 bp region of the SARS-CoV-2 spike protein (38). The standard samples were serial 10-fold dilutions of a known copy number of the HKU1 virus. The results were normalized and expressed as genome equivalent copies per gram of tissue.

Infectious viral load measurement. Lungs from infected mice were collected and homogenized. Confluent monolayers of Vero E6 cells were infected with serial dilutions of supernatants obtained from the lung homogenates. The immuno-plaque assay with the SARS-CoV-2 NP antibody was performed to measure the viral load.

Measurement of anti-spike antibody. His-tagged full-length SARS-CoV-2 S protein (Cat. # 40589-V0881, Sino Biological) was used as a coating protein. The plate was incubated with mouse serum samples for 2 h. The HRP-conjugated goat anti-mouse IgG antibody (Cat. # 05-4220, Invitrogen) was used as the detecting antibody. Absorbance was measured at 450 nm by a Multiskan FC Microplate Photometer (Fisher Scientific).

Human ACE2 RNA quantification. Total RNA from the indicated tissues of the K18-hACE2 mice was isolated using the PureLink RNA minikit (Invitrogen), and cDNA was synthesized using SuperScript Reverse Transcriptase (Thermo Fisher). Human ACE2 expression was examined using the following primers: F: CGAAGGCGAGACCTGCTCTA; R: GGGCGAAGTGGGAGCAGTTCC, under the following PCR conditions: 98°C for 30 s, followed by 40 cycles of 98°C for 15 s, 62°C for 30 s, and 72°C for 60 s.

Immunohistochemistry and HandE staining. Tissues were harvested from the infected K18-hACE2 mice and immediately fixed in 10% neutral buffered formalin. Dehydration, clearing, and paraffinization were performed on a Tissue-Tek VIP Vacuum Infiltration Processor (SAKURA). The samples were embedded in paraffin using a Tissue-Tek TEC Tissue Embedding Station (SAKURA). Samples were then
REFERENCES

January Volume 96 Issue 1 e00964-21 jvi.asm.org

ACKNOWLEDGMENTS

We declare that we have no conflicts of interest.

REFERENCES

1. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. 2020. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 172:577–582. https://doi.org/10.7326/M20-0504.

2. WHO. 2021. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19).

3. Gibson PG, Qin L, Puah SH. 2020. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med J Aust 213:54–56.e1. https://doi.org/10.5694/mja2.50674.

4. Steenblock C, Schwarz PEH, Ludwig B, Linkermann A, Zimmet P, Bornstein SR. 2021. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol 9:786–798. https://doi.org/10.1016/S2213-8587(21)00244-8.

5. Liu Y, Sawahla AH, Lu Q. 2021. COVID-19 and autoimmune diseases. Curr Opin Rheumatol 33:155–162. https://doi.org/10.1097/BOR.0000000000001576.

6. Saad MA, Alshfawy M, Nasser M, Mohamed M, Esene IN, Elbendary A. 2021. COVID-19 and autoimmune diseases: a systematic review of reported cases. Curr Rheumatol Rev 17:193–204. https://doi.org/10.2174/1573397116666201029155856.

7. Brodin P. 2021. Immune determinants of COVID-19 disease presentation and severity. Nat Med 27:28–33. https://doi.org/10.1038/s41591-020-01202-8.

8. Blot M, Bour JB, Quenot JP, Bourredjem A, Nguyen M, Guy J, Monier S, Georges M, Large A, Dargent A, Guilhem A, Mouries-Martin S, Benbar J, Bouroumadi B, Lachere P, Chavanet P, Binquet C, Piroth L, the LYMPHONIE study group. 2020. The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome. J Transl Med 18:357. https://doi.org/10.1186/s12967-020-02646-9.

9. Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, Mencarini J, Caporale R, Peruzzi B, Antonelli A, Trotta M, Zammaroli L, Ciani L, Gori L, Lazzeri C, Matucci A, Vultaggio A, Rossi O, Almerigogna F, Paroncini P, Fontanari P, Laborini F, Peris A, Rossolini GM, Bartoloni A, Romagnani S, Liotta F, Annunziato F, Cosmi L. 2020. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest 130:4694–4703. https://doi.org/10.1172/JCI138354.

10. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Yeeles D. 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181:281–292.e6. https://doi.org/10.1016/j.cell.2020.02.058.

11. McCray PB, Jr, Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, Nettland J, Jia HP, Netland J, Lee A, Saldanha J, Chen T, Liu Y, Li WP, Li BD, Li N, Pan G, Redfield R, Williams S, Park YJ, Tortorici MA, et al. 2020. Genetic variations in the 2019 novel coronavirus (2019-nCoV) influence the ability of the anchorless receptor-binding domain to interact with cell surface receptors and control spike protein dimerization. Cell 181:293–309.e21. https://doi.org/10.1016/j.cell.2020.06.062.
Perelman S. 2007. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol 81:813–821. https://doi.org/10.1128/JVI.02012-06.

12. Jiang RD, Liu MQ, Chen C, Shan Z, You YW, Shen XR, Li Q, Zhang L, Zhu Y, Si HR, Wang Q, Min J, Wang X, Zhang W, Li B, Zhang HJ, Baric RS, Zhou P, Yang XL, Shi ZL. 2020. Pathogenesis of SARS-CoV-2 in Transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182:50–58.e8. https://doi.org/10.1016/j.cell.2020.05.027.

13. Bao L, Deng W, Huang G, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F, Gu Y, Li F, Lv Q, Wang W, Xue J, Gong G, Liu M, Wang G, Wang S, Song Z, Zhao L, Liu P, Zhao L, Ye F, Wang H, Zhou Z, Zhu N, Zhen W, Yu H, Zhang X, Guo L, Chen L, Wang C, Wang Y, Xiao Q, Sun Y, Liu H, Zuo F, Ma C, Yan L, Yang M, Han J, Xu W, Tan W, Peng X, Jin Q, Wu G, Qin C. 2020. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583:830–833. https://doi.org/10.1038/s41586-020-2312-y.

14. Sun SH, Chen Q, Gu HJ, Yang G, Wang YX, Huang XY, Liu SS, Zhang NN, Li XF, Xiong R, Guo Y, Deng YQ, Huang WJ, Liu Q, Liu QM, Shen YL, Zhou Y, Yang X, Zhao T, Fan CF, Zou YH, Qin CF, Wang Y. 2020. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28: 124–133.e4. https://doi.org/10.1016/j.chom.2020.05.020.

15. Hassan AO, Case JB, Winkler ES, Ackrout LB, Bailey AL, McCune BT, Fox JM, Chen RE, Aloussi WB, Turner JS, Schmitz AJ, Lei T, Shihrani S, Keeler FP, Freemont DH, Greco S, McCray PB, Jr, Perelman S, Holtzman MJ, Elledy AH, Diamond NS. 2020. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 174:744–753.e4. https://doi.org/10.1016/j.cell.2020.06.011.

16. Oladunni FS, Park JG, Pino PA, Gonzalez O, Akhter A, Allue-Guardia A, Olmo-Fontanez A, Gautam S, Garcia-Vilaro A, Ye C, Chiem M, Headley C, Dwiwedi V, Parodi LM, Alfonso KJ, Staples HM, Schami A, Garcia JI, Whigham A, Platt RN, 2nd, Gazi M, Martinez J, Chuba C, Earley S, Rodriguez OH, Mdaki SD, Kavelish KN, Hallam CRA, Christie C, Patterson JL, Anderson T.C, Carrion R, Jr, Dick EJ, Jr, Hall-Urso S, Schlesinger LS, Alvarez X, Kihshen H, Politanska Y, Sichizya L, Kang M, Shilatifard A, Guzmán ER, Abbott DA, Donnelly HK, Donayre A, Goldberg IA, Klug ZM, Ellebedy AH, Diamond MS. 2020. A SARS-CoV-2 infection model in mice replicates human pulmonary disease in COVID-19. Cell Mol Immunol 17:6122. https://doi.org/10.1038/s41423-020-0348-w.

17. Grant RA, Morales-Nebreda L, Markov NS, Swaminathan S, Querrey M, Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, McCune BT, Fox JM, Chen RE, Alsoussi WB, Turner JS, Schmitz AJ, Lei T, Shrihari S, Keeler FP, Freemont DH, Greco S, McCray PB, Jr, Perelman S, Holtzman MJ, Boucher RC, Gralinski LE, Montgomery SA, Baric RS. 2020. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183:1070–1085.e12. https://doi.org/10.1016/j.cell.2020.09.050.

18. Dinnon KH, 3rd, Leist SR, Schafer A, Edwards CE, Martinez DR, Montgomery SA, West A, Youngblut BL, Jr, Hou YJ, Adams LE, Gully KL, Brown AJ, Huang E, Bryant MD, Choong IC, Glenn JS, Gralinski LE, Sheehan TP, Baric RS. 2020. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586:560–566. https://doi.org/10.1038/s41586-020-2708-8.

19. Huang K, Zhang Y, Hui X, Zhao Y, Gong W, Wang T, Zhang S, Yang Y, Deng F, Zhang Q, Chen X, Yang Y, Sun X, Chen H, Tao YJ, Zou Z, Jin M. 2021. Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice. eLifeBiology 67:103381. https://doi.org/10.1016/j.cell.2021.103381.

20. Sepehrinezhad A, Shabahzi A, Negah SS. 2020. COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review. Neuro Virol 26:324–329. https://doi.org/10.1111/nerv.12750.

21. Muhammad S, Petridis A, Cornelius JF, Hanggi D. 2020. Letter to editor: severe brain haemorrhage and concomitant COVID-19 infection: a neurovascular complication of COVID-19. Brain Behav Immun 87:150–151. https://doi.org/10.1016/j.bbi.2020.05.015.

22. Mao XY, Jin WL. 2020. The COVID-19 pandemic consideration for brain infection. Neuroscience 437:130–131. https://doi.org/10.1016/j.neuroscience.2020.04.044.

23. Ramani A, Pranty AI, Gopalakrishnan J. 2021. Neurotropic effects of SARS-CoV-2 modeled by the human brain organoids. Stem Cell Rep 16:373–384. https://doi.org/10.1016/j.stemcr.2021.02.007.

24. Pellegrini L, Albecka A, Mallery DL, Kellner MJ, Paul D, Carter AP, James LC, Lancaster MA. 2020. SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids. Cell Stem Cell 27:931–941.e5. https://doi.org/10.1016/j.stem.2020.10.001.

25. Zhang BZ, Chu H, Han S, Shuai H, Deng J, Hu YF, Gong HR, Lee AC, Zou Z, Yau T, Wu W, Hung IF, Chan JF, Yuen KY, Huang JD. 2020. SARS-CoV-2 disrupts the blood-CSF barrier in human brain organoids. Cell Stem Cell 16:373–384. https://doi.org/10.1016/j.stem.2020.06.032.

26. Cooper KW, Brain DH, Farruggia MC, Bhutani S, Pellegrino R, Tsukahara T, Weinreb C, Joseph PV, Larson ED, Parma V, Albers MW, Barlow LA, Datta SR, Di Pietro A. 2020. COVID-19 and the chemical senses: supporting players take center stage. Neuron 107:219–233. https://doi.org/10.1016/j.neuron.2020.06.032.

27. Dong W, Wang J, Tian L, Zhang J, Mead H, Jaramillo SA, Li A, Zumwalt RE, Whelan SPJ, Settles EW, Keim PS, Barker BM, Caligiuri MA, Barker BM, Yu J. 2021. FXa inhibitor of cellular poly(ADP-ribose) polymerase, blocks replication of the SARS-CoV-2 spike protein and blocks cell entry to protect against SARS-CoV-2 infection in B.1.1.7 variant. bioRxiv. https://doi.org/10.1101/2021.06.07.447437.

28. Stone NE, Jaramillo SA, Jones AN, Vazquez AJ, Martz M, Versluis LM, Ramani P, Sprague AC, Barlow LA, Saha SK, Cohn K, Nelson KE, Ryan K, Reck J, Hennessey K, Headley C, Christie C, Gray J, Gao H. 2020. SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28: 1085.e12. https://doi.org/10.1016/j.chom.2020.09.020.

29. Charo IF, Abraham RT. 2021. The role of angiotensin-converting enzyme 2 in human health and disease. J Clin Invest 131:3846–3852. https://doi.org/10.1172/JCI147818.